Complete financial analysis of Novan, Inc. (NOVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novan, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- First Hydrogen Corp. (FHYD.V) Income Statement Analysis – Financial Results
- Shanghai Aiyingshi Co.,Ltd (603214.SS) Income Statement Analysis – Financial Results
- Scout Security Limited (SSECF) Income Statement Analysis – Financial Results
- Zuari Industries Limited (ZUARIGLOB.NS) Income Statement Analysis – Financial Results
- Silverlake Axis Ltd (SLVFF) Income Statement Analysis – Financial Results
Novan, Inc. (NOVN)
About Novan, Inc.
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.61M | 2.82M | 4.21M | 4.48M | 5.99M | 2.14M | 0.00 | 0.00 | 112.00K |
| Cost of Revenue | 7.38M | 0.00 | 0.00 | 25.17M | 23.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.23M | 2.82M | 4.21M | -20.70M | -17.05M | 2.14M | 0.00 | 0.00 | 112.00K |
| Gross Profit Ratio | 68.74% | 100.00% | 100.00% | -462.25% | -284.66% | 100.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 15.99M | 20.42M | 19.81M | 25.17M | 23.05M | 25.21M | 46.49M | 16.57M | 6.77M |
| General & Administrative | 0.00 | 12.34M | 11.27M | 10.41M | 11.51M | 0.00 | 13.34M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.10M | 12.34M | 11.27M | 10.41M | 11.51M | 13.11M | 13.34M | 9.27M | 5.17M |
| Other Expenses | 1.53M | -136.00K | -712.00K | -419.00K | 72.00K | 0.00 | 127.00K | 0.00 | 0.00 |
| Operating Expenses | 51.62M | 32.62M | 30.37M | 35.17M | 34.55M | 38.33M | 59.83M | 25.83M | 11.94M |
| Cost & Expenses | 59.00M | 32.62M | 30.37M | 35.17M | 34.55M | 38.33M | 59.83M | 25.83M | 11.94M |
| Interest Income | 53.00K | 13.00K | 51.00K | 177.00K | 297.00K | 0.00 | 81.00K | 48.00K | 58.00K |
| Interest Expense | 1.45M | 0.00 | 0.00 | 2.00K | 1.05M | 0.00 | 2.00K | 1.00K | 701.00K |
| Depreciation & Amortization | 1.63M | -384.00K | 6.14M | 2.35M | 1.66M | 1.42M | 757.00K | 631.00K | 462.00K |
| EBITDA | -33.76M | -30.30M | -24.07M | -28.34M | -26.53M | -33.82M | -59.83M | -25.16M | -11.31M |
| EBITDA Ratio | -142.99% | -1,073.67% | -572.10% | -633.06% | -442.80% | -1,580.37% | 0.00% | 0.00% | -10,096.43% |
| Operating Income | -35.39M | -29.92M | -30.21M | -30.69M | -28.56M | -36.19M | -59.83M | -25.83M | -11.83M |
| Operating Income Ratio | -149.90% | -1,060.06% | -718.01% | -685.46% | -476.73% | -1,690.89% | 0.00% | 0.00% | -10,560.71% |
| Total Other Income/Expenses | 4.08M | 223.00K | 921.00K | 47.00K | 0.00 | -942.00K | 127.00K | 48.00K | -1.28M |
| Income Before Tax | -31.31M | -29.69M | -29.29M | -30.64M | -12.67M | -37.13M | -59.70M | -25.79M | -13.10M |
| Income Before Tax Ratio | -132.62% | -1,052.16% | -696.13% | -684.41% | -211.53% | -1,734.91% | 0.00% | 0.00% | -11,699.11% |
| Income Tax Expense | -11.75M | -855.00K | 870.00K | 138.00K | -15.89M | 942.00K | -757.00K | 2.28M | -1.01M |
| Net Income | -19.56M | -28.84M | -30.16M | -30.78M | -12.67M | -37.13M | -59.70M | -28.06M | -11.39M |
| Net Income Ratio | -82.85% | -1,021.86% | -716.80% | -687.49% | -211.53% | -1,734.91% | 0.00% | 0.00% | -10,167.86% |
| EPS | -0.89 | -1.69 | -3.05 | -11.72 | -4.91 | -23.23 | -99.73 | -25.11 | -10.19 |
| EPS Diluted | -0.89 | -1.69 | -3.05 | -11.72 | -4.91 | -23.23 | -99.73 | -25.11 | -10.19 |
| Weighted Avg Shares Out | 22.02M | 17.07M | 9.88M | 2.63M | 2.58M | 1.60M | 598.60K | 1.12M | 1.12M |
| Weighted Avg Shares Out (Dil) | 22.02M | 17.07M | 9.88M | 2.63M | 2.58M | 1.60M | 598.60K | 1.12M | 1.12M |
Novan to Host Corporate Update Conference Call and Webcast on September 9, 2021
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q2 2021 Results - Earnings Call Transcript
Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Novan to Report Second Quarter 2021 Financial Results on August 12, 2021
Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
Novan Stock Increases Over 10%: Why It Happened
Novan Announces Inclusion in Russell Microcap® Index
Novan Announces Closing of $40 Million Public Offering of Common Stock
Novan Stock Falls After Raising $40M Via Equity At 21% Discount
NOVN Stock Price Falls Over 10% Pre-Market: Why It Happened
Source: https://incomestatements.info
Category: Stock Reports